Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Clin Cases. Aug 16, 2025; 13(23): 101742
Published online Aug 16, 2025. doi: 10.12998/wjcc.v13.i23.101742
Table 1 Clinical information of the training and validation cohorts, n (%)/mean ± SD
Characteristics
Training cohort (n = 85)
Validation cohort (n = 37)
P value
Sex0.430
Male73 (85.9)33 (89.2)
Female12 (14.1)4 (10.8)
Age54.35 ± 10.93057.43 ± 10.2190.147
Child-Pugh class0.213
A67 (78.8)26 (70.3)
B18 (21.2)11 (29.7)
Hepatitis0.040
None4 (4.7)1 (2.7)
Hepatitis B79 (92.9)32 (86.5)
Hepatitis C1 (1.2)1 (2.7)
Alcoholic hepatitis1 (1.2)3 (8.5)
PT (s)0.458
≤ 1480 (94.1)34 (91.9)
> 145 (5.9)3 (8.1)
TB (μmol/L)0.173
≤ 17.141 (48.2)22 (59.5)
> 17.144 (51.8)15 (40.5)
ALB (g/L)
0.144
≤ 3545 (52.9)15 (40.5)
> 3540 (47.1)22 (59.5)
AST (U/L)0.357
≤ 4018 (21.2)6 (16.2)
> 4067 (78.8)31 (83.8)
ALT (U/L)0.194
≤ 5059 (69.4)22 (59.5)
> 5026 (30.6)15 (40.5)
AFP (ng/mL)0.326
≤ 40027 (31.8)14 (37.8)
> 40058 (68.2)23 (62.2)